Role of chemotherapy in the treatment of thymoma: Patients with progressive thymoma are treated with single-agent chemotherapy in the initial phase of chemotherapy. Single-agent chemotherapeutic agents include cisplatin, interleukin 2, pemetrexed, isocyclophosphamide, and octreotide. Although, these drugs are effective in thymoma, they are mostly clinical phase II trials and the number of patients in each study is small and inconclusive, but they have shown the effectiveness of platinum-based chemotherapy. Lin Min, Department of Thoracic Surgery, The First Affiliated Hospital of Fujian Medical University Preoperative induction therapy and radiotherapy for inoperable thymoma: In clinical practice, nearly 1/3 of patients with thymoma are inoperable due to local progression at the time of diagnosis. It has been shown that preoperative chemotherapy or radiotherapy can improve the surgical resection rate and long-term survival of patients with locally progressive thymoma. It is clear that preoperative induction therapy can lead to complete surgical resection in nearly half of patients with locally advanced thymoma, and therefore a multidisciplinary discussion should be held to determine the treatment modality before treating this group of patients. For patients with thymoma not amenable to surgical treatment, radiotherapy is undoubtedly the treatment of choice, and radiotherapy combined with chemotherapy needs to be supported by additional clinical trials. Management of thymoma recurrence and distant metastases: The main causes of thymoma treatment failure are local recurrence and distant metastases. The lung and pleura are the main sites of thymoma metastasis and recurrence. Compared with patients with primary treatment, patients with metastasis and recurrence of thymoma have relatively poor prognosis, but after active retreatment, they can still obtain more satisfactory treatment results. Clinically, we should treat this group of patients positively and explore reasonable individualized treatment modes. The International Thymic Tumor Cooperative Research Organization was established: Thymoma is a rare tumor, and there are few prospective randomized controlled clinical studies. In order to accelerate scientific collaboration and accumulate more clinical data on thymic tumors, the first international thymic tumor cooperative was established in 2010, namely ITMIG, a registered non-profit academic organization whose mission is to promote clinical and basic research on thymic malignancies. The foundation was created with funding from thymic tumor patients and their families.